To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.

1) **What happened and status:** Rep. Landsman (D-OH) introduced HR7877 on March 9, 2026, with 5 cosponsors. It was referred to the House Committee on Energy and Commerce. The sponsor delivered introductory remarks on March 17. This is an early-stage authorization bill — not a live market-moving event. The bill has low legislative momentum given the limited cosponsorship and absence of companion Senate legislation. 2) **The money trail:** HR7877 authorizes the HHS Secretary to conduct a 2-year demonstration program — it does NOT appropriate any funding. The bill specifies that wound care supplies and OTC drugs must be covered as mandatory Medicaid benefits during the demo, meaning state Medicaid programs bear the reimbursement cost. No federal funding is explicitly authorized or appropriated in the bill text for administrative costs, data collection, or provider reimbursement. This is a policy mandate on states, not a federal spending program. 3) **Structural winners and losers:** The direct beneficiaries are manufacturers of wound care dressings and OTC drugs (antiseptics, antibiotic ointments, zinc oxide). These include (Janssen pharma and Ethicon wound care), (retail pharmacy dispensing), and $CAH (wholesale distribution of medical supplies). However, the EB patient population on Medicaid is estimated at only 3,000-5,000 individuals nationally — even a generous spending estimate of $5,000-10,000 per patient annually yields a total market of $15M-$50M, which is negligible for any of these companies. 4) **Real market data analysis:** The provided real market data shows at $228.88 (30-day -6.37%) and at $82.99 (30-day +15.55%). $CAH has dropped sharply to $190.81 (30-day -9.71%). None of these movements correlate with this bill — CVS's surge reflects broader managed care and PBM sector trends, while JNJ's decline mirrors pharma sector weakness. $CAH's 30-day decline of 9.71% is tied to wholesale distribution headwinds, not EB legislation. 5) **Timeline and legislative path:** The bill must pass the Energy and Commerce Committee, then the full House, then the Senate (no companion bill exists), then be signed into law. With 5 cosponsors and a single-party sponsor, this is unlikely to advance in a divided 119th Congress. The earliest potential enactment would be late 2026 or 2027. Even if passed, the 2-year demonstration would not begin until at least 1 year after enactment.